Home
    • Plans Blog Contact
    Insulet Corporation logo

    Insulet Corporation

    PODD
    Last price US$143.98
    Market cap US$11.3b
    12M price change -54.40%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    AmerisourceBergenABC Industry peer NuVasive IncNUVA Industry peer Computer Programs and Systems IncCPSI Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Insulet Corporation Overview

    Industry: Healthcare Equipment & Supplies

    Sector: Healthcare

    Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the hand Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Insulet Corporation into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 05, 2026

    Quarterly result summary

    Revenue was $801.7M (+23.5% YoY). Operating income was $129.7M. Net income was $95M.

    Revenue $801.7M +23.5% YoY
    Operating income $129.7M reported
    Net income $95M reported
    Adjusted EBITDA $199.8M +702% YoY

    What changed

    • Revenue +23.5% YoY to $801.7M.
    • Adjusted EBITDA +702% YoY to $199.8M.
    • Operating income of $129.7 million, or 16.2% of revenue, down 250 basis points over prior year.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 05, 2026 SEC filing 8-K Aug 05, 2026 SEC filing 8-K May 06, 2026 SEC filing 10-Q May 06, 2026 Earnings release Earnings release May 06, 2026 SEC filing 10-K Feb 18, 2026 SEC filing 8-K Feb 18, 2026 Earnings release Earnings release Feb 18, 2026 SEC filing 8-K Nov 06, 2025 Earnings release Earnings release Nov 06, 2025 SEC filing 10-Q Nov 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Insulet Corporation boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Healthcare Equipment & Supplies industry , AmerisourceBergen , NuVasive Inc , Computer Programs and Systems Inc are companies with high ratings.

    Return on Equity

    Score 3.22/5
    Insulet Corporation stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Insulet Corp... PODD US$11.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 4.42/5
    Insulet Corporation commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Insulet Corp... PODD US$11.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Healthcare Equipment & Supplies industry , AmerisourceBergen , NuVasive Inc , Computer Programs and Systems Inc are companies with high ratings.

    Leverage

    Score 1.33/5
    Insulet Corporation registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Insulet Corp... PODD US$11.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Insulet Corporation logo

    Insulet Corporation

    US$143.98

    US$84.29

    -41.5% vs price

    US$11.3b

    1.40%

    -54.40%